Related Experiment Video
Updated: Aug 31, 2025
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
Pain and Opioid-Induced Gut Microbial Dysbiosis
Karen R Thomas1, Jacob Watt1, Chuen Mong J Wu1
1School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Abstract:
Opioid-induced dysbiosis (OID) is a specific condition describing the consequences of opioid use on the bacterial composition of the gut. Opioids have been shown to affect the epithelial barrier in the gut and modulate inflammatory pathways, possibly mediating opioid tolerance or opioid-induced hyperalgesia; in combination, these allow the invasion and proliferation of non-native bacterial colonies. There is also evidence that the gut-brain axis is linked to the emotional and cognitive aspects of the brain with intestinal function, which can be a factor that affects mental health. For example, Mycobacterium, Escherichia coli and Clostridium difficile are linked to Irritable Bowel Disease; Lactobacillaceae and Enterococcacae have associations with Parkinson's disease, and Alistipes has increased prevalence in depression. However, changes to the gut microbiome can be therapeutically influenced with treatments such as faecal microbiota transplantation, targeted antibiotic therapy and probiotics. There is also evidence of emerging therapies to combat OID. This review has collated evidence that shows that there are correlations between OID and depression, Parkinson's Disease, infection, and more. Specifically, in pain management, targeting OID deserves specific investigations.
Insights
Opioid-induced dysbiosis (OID) alters gut bacteria, impacting the gut-brain axis and mental health. Emerging therapies show promise for OID, highlighting its importance in pain management.
Area of Science:
- Microbiology
- Neuroscience
- Gastroenterology
Background:
- Opioid-induced dysbiosis (OID) describes gut microbiome alterations from opioid use.
- Opioids disrupt the gut epithelial barrier and inflammatory pathways, promoting non-native bacterial growth.
- The gut-brain axis links gut health to mental and cognitive functions.
Purpose of the Study:
- To review the correlations between OID and various health conditions.
- To highlight the potential therapeutic interventions for OID.
- To emphasize the need for further investigation into OID in pain management.
Main Methods:
- Literature review of studies investigating OID.
- Analysis of evidence linking gut microbiome changes to specific diseases.
- Exploration of current and emerging OID therapies.
Main Results:
- OID is associated with conditions such as Irritable Bowel Disease, Parkinson's Disease, and depression.
- Specific bacterial species like *Mycobacterium*, *Escherichia coli*, *Clostridium difficile*, *Lactobacillaceae*, *Enterococcacae*, and *Alistipes* are linked to these conditions.
- Therapeutic strategies including fecal microbiota transplantation, antibiotics, and probiotics can influence gut microbiome changes.
Conclusions:
- OID has significant implications for mental health and neurological disorders.
- Targeting OID presents a potential therapeutic avenue, particularly in pain management.
- Further research is warranted to fully understand and treat OID.
More Related Videos
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Related Concept Videos
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:25Analgesia and Pain Management
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...